Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16719668 | 0.78 | GRM5 (0.43) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL30119037 | 0.77 | GRM5 (0.57) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL18125286 | 0.76 | FFAR1 (0.38) | GRM5 | |
| SCHEMBL16720356 | 0.75 | GRM5 (0.48) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL16720114 | 0.72 | DHODH (0.44) | GRM5 | |
| SCHEMBL16719945 | 0.72 | KDM4E (0.36) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL16719454 | 0.72 | GRM5 (0.40) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL16720340 | 0.71 | GRM5 (0.43) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL16720324 | 0.69 | NPC1 (0.40) | GRM5 | |
| SCHEMBL31472797 | 0.69 | CCNC (0.37) | GRM5PIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | MCM5, EBNA1BP2, MLLT1 | GRM5 3154/4885PIK3CD 1689/4885PIK3R1 1788/4885 |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | GRM5 3225/4885PIK3CD 2076/4885PIK3R1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.